ReviewNature medicine2023
The landscape of cancer research and cancer care in China.
Review in Nature medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Comparison of treatment efficacy of targeted therapies approved in China for non-small cell lung cancer before and after the introduction of accelerated drug marketing registration procedures.International journal of clinical pharmacy · 2026Pooled it
- Regulatory and clinical outcomes of priority-reviewed innovative cancer drugs in China between 2015 and 2024: an observational study.BMC cancer · 2025Pooled it
- Safety and feasibility of robot-assisted remote radical gastrectomy for gastric cancer based on 5G communication technology (FUTURE-04): a prospective, single-arm clinical trial.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2026Trial
- Multimodal radiopathomics model predicts postoperative metachronous liver metastasis in gastric cancer.Nature communications · 2026Article
- Cancer burden and control in China: landscape, trends and challenges.Nature reviews. Clinical oncology · 2026Review
- Neural regulation of cancer: from microenvironmental hijacking to systemic circuit co-option.Cellular oncology (Dordrecht, Netherlands) · 2026Review
- Accelerating the clinical translation of bioengineered anticancer therapeutics.Journal of the National Cancer Center · 2026Article
- Tissue-derived small extracellular vesicles in cancer diagnosis and prognosis: current insights and future directions.Cell communication and signaling : CCS · 2026Review
- Disease burden of hematological malignancies worldwide, in China and in the United States based on the GLOBOCAN 2022 and Global Burden of Disease 2021 data.Chinese medical journal · 2026Article
- Bridging mechanism and clinic: unlocking the full potential of oncolytic virus-based immunotherapy.Molecular cancer · 2026Review
- Interpretable machine learning-based survival prediction and key gene identification in cancer using gene expression and clinical data.Translational cancer research · 2026Article
- A Dual-Perspective Comparison of Classical and Clinic-Based Multidisciplinary Team Models in Cancer Care: A Cross-Sectional and Qualitative Study.Health science reports · 2026Article
- Novel intermolecular zinc fingers and redox-driven conformational changes dictate tumor suppressor ZMYND11's role in cooperative recognition of diverse targets.Nucleic acids research · 2026Article
- Serine inhibits granulosa cell ferroptosis to maintain ovarian function.Nature communications · 2026Article
- Vessels encapsulating tumor clusters in hepatocellular carcinoma: a distinct metastatic pathway with diagnostic and therapeutic significance.Journal of translational medicine · 2026Review
- Cross-sectional study on the current status of county-level cancer prevention and treatment capabilities in the four southwestern provinces of China.Frontiers in public health · 2026Article
- Acupuncture in remodeling the tumor microenvironment: current status and challenges.Frontiers in immunology · 2026Review
- Optimizing CAR T cell therapy for solid tumours: a clinical perspective.Nature reviews. Clinical oncology · 2025Review
- Near-Infrared Conjugated Macrocyclic BODIPYs for Photothermal Cancer Therapy.Angewandte Chemie (International ed. in English) · 2025Article
- Decoding the functional roles of circular RNAs linked to NF-κB pathway in carcinogenesis.Discover oncology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
The rising cancer incidence rate in China poses a substantial public health concern, although there have been remarkable improvements in the country's cancer mortality and survival rates. In this Review, we outline the current landscape and future directions of cancer care and research in China. We discuss national screening programs and strategies for cancer detection and delve into the evolving landscape of cancer care, emphasizing the adoption of multidisciplinary, comprehensive treatment and precision oncology. Additionally, we examine changes in drug research and development policies that have enabled approval of new drugs. Finally, we look to the future, highlighting key priorities and identifying gaps. Effectively addressing challenges and seizing opportunities associated with cancer research in China will enable the development of targeted approaches to alleviate the global burden of cancer.
Indexed as
Identifiers
38087112What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.